Different hepatitis B carrier categories need different management strategies in case of immunosuppressive chemotherapeutic regimens.

Gigante, E; Deli, I; Gallina, S; De Santis, E; Delle Fave, G; Marignani, M

Gigante, E; Deli, I; Gallina, S; De Santis, E; Delle Fave, G; Marignani, M.

Afiliação

Gigante E; Digestive and Liver Disease Department, Second Medical Faculty, University "Sapienza", Azienda Ospedaliera S. Andrea, Rome, Italy. Electronic address: whitegiant@hotmail.it.
Deli I; Digestive and Liver Disease Department, Second Medical Faculty, University "Sapienza", Azienda Ospedaliera S. Andrea, Rome, Italy.
Gallina S; Digestive and Liver Disease Department, Second Medical Faculty, University "Sapienza", Azienda Ospedaliera S. Andrea, Rome, Italy.
De Santis E; Digestive and Liver Disease Department, Second Medical Faculty, University "Sapienza", Azienda Ospedaliera S. Andrea, Rome, Italy.
Delle Fave G; Digestive and Liver Disease Department, Second Medical Faculty, University "Sapienza", Azienda Ospedaliera S. Andrea, Rome, Italy.
Marignani M; Digestive and Liver Disease Department, Second Medical Faculty, University "Sapienza", Azienda Ospedaliera S. Andrea, Rome, Italy.

Ann Oncol ; 22(6): 1462-1463, 2011 Jun.

Article em En | MEDLINE | ID: mdl-21525405

Assuntos

Anticorpos Monoclonais Murinos/efeitos adversos; Antineoplásicos/efeitos adversos; Vírus da Hepatite B; Hepatite B/induzido quimicamente; Transtornos Linfoproliferativos/tratamento farmacológico; Feminino; Humanos; Masculino

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Vírus da Hepatite B / Anticorpos Monoclonais Murinos / Hepatite B / Transtornos Linfoproliferativos / Antineoplásicos Limite: Female / Humans / Male Idioma: En Revista: Ann Oncol Assunto da revista: NEOPLASIAS Ano de publicação: 2011 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google